



**PRESS RELEASE: 3 November 2003**

## **Lectus Therapeutics Ltd announces financing from the SULIS Seedcorn Fund**

Lectus Therapeutics Limited ('LTL'), an emerging UK-based bio-pharmaceutical company, today announced it had closed a deal for seed financing from the SULIS Seedcorn fund. LTL's vision is to become a world leader in developing ion channel therapeutics with an enhanced safety profile.

LTL will exploit the power of its proprietary functional proteomics platform, LEPTICS™ (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and build on its knowledge of ion channels and protein-protein interactions, to develop next-generation ion channel modulators.

Roland Kozlowski, CEO of LTL, said, "Lectus Therapeutics has received its seed financing in a difficult market, which highlights the potential value of proteomics for the discovery of novel drugs that work on ion channels."

Iain Wilcock, Investment Manager for SULIS commented, "We are delighted to have the opportunity to work with Lectus Therapeutics as they move forward in developing their business. This is a perfect example of the type of company our university challenge funds seek to support."

### **Contacts for further information:**

Dr. Roland Kozlowski, CEO  
Lectus Therapeutics Ltd

Tel: +44 (0)1993 810029  
Fax: +44 (0)1993 813639

roland.kozlowski@lectusth.com  
www.lectustherapeutics.com

Iain Wilcock, Quester  
Investment Manager for Sulis

Tel: +44 (0) 207 222 5472  
Fax: +44 (0) 207 878 3244

iain.wilcock@questor.co.uk  
www.questor.co.uk  
www.bath.ac.uk/sulis-innovation

## **Notes for editors**

### **About Lectus Therapeutics Limited (LTL)**

Lectus Therapeutics Limited (LTL) is an emerging UK-based bio-pharmaceutical company, incorporated in December 2002, specialising in the discovery and development of novel drugs for diseases associated with smooth muscle hyper reactivity. LTL's vision is to become a world leader in developing ion channel therapeutics with an enhanced safety profile.

LTL will exploit the power of its proprietary functional proteomics platform, LEPTICS™ (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and build on its knowledge of ion channels and protein-protein interactions, to develop next-generation ion channel modulators that offer important clinical and economic advantages over existing therapies.

### **About Sulis**

The Sulis Seedcorn Fund provides support for the early stage commercialisation of research generated by the Universities of Bath, Bristol and Southampton. The Fund offers resources for targeted development work to enhance the commercial potential of specific products or services as well as for licensing, sale of intellectual property and formation of spin-out companies.